Literature DB >> 23819814

Association of genetic polymorphisms in matrix metalloproteinase-9 and coronary artery disease in the Chinese Han population: a case-control study.

Hai-di Wu1, Xiao Bai, Dong-mei Chen, Hong-yan Cao, Ling Qin.   

Abstract

OBJECTIVE: Matrix metalloproteinase-9 (MMP-9) plays an important role in inflammation and matrix degradation involved in atherosclerosis and plaque rupture. The T allele of rs3918242 has been reported to lead to a high promoter activity and associate with the extent of coronary artery disease (CAD). And some studies have reported that the G allele of rs17576 might be associated with CAD. The aim of this study was to assess the association between the polymorphisms of the MMP-9 gene and CAD in the Chinese Han population.
METHODS: This case-control study comprised 258 CAD cases and 153 controls from the Chinese Han Population. The genomic DNA of MMP-9 was isolated from whole blood. Polymerase chain reaction-based restriction fragment length polymorphism was used to determine the rs3918242 and rs17576 genotypes in the MMP-9 gene and the total serum levels of MMP-9 were measured using enzyme-linked immunosorbent assay in both case and control groups.
RESULTS: Analysis of MMP-9 gene polymorphisms showed that the frequencies of the T allele and CT+TT genotypes of rs3918242 were significantly higher in the case group than in the control group (p<0.05). However, the distribution of variant genotypes of rs17576 did not differ between the case and control groups (p>0.05). The total serum level of MMP-9 was significantly higher in the case group than in the control group (p<0.05). The subjects carrying T alleles in the CAD group had higher average serum MMP-9 levels compared with CC genotypes (p<0.05).
CONCLUSIONS: Our results suggest that the single-nucleotide polymorphism of rs3918242 in the MMP-9 gene is associated with CAD and high serum levels of MMP-9 are also associated with CAD in the Chinese Han population. Therefore, genetic variation of rs3918242 may participate in the development of CAD through influencing MMP-9 expression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23819814      PMCID: PMC3761435          DOI: 10.1089/gtmb.2013.0109

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  29 in total

Review 1.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry.

Authors:  Robert Visse; Hideaki Nagase
Journal:  Circ Res       Date:  2003-05-02       Impact factor: 17.367

Review 2.  The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosis.

Authors:  Sylvia Heeneman; Jack P Cleutjens; Birgit C Faber; Esther E Creemers; Robert-Jan van Suylen; Esther Lutgens; Kitty B Cleutjens; Mat J Daemen
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

Review 3.  Metalloproteinases and their inhibitors in matrix remodeling.

Authors:  L M Matrisian
Journal:  Trends Genet       Date:  1990-04       Impact factor: 11.639

4.  The structural basis for the elastolytic activity of the 92-kDa and 72-kDa gelatinases. Role of the fibronectin type II-like repeats.

Authors:  J M Shipley; G A Doyle; C J Fliszar; Q Z Ye; L L Johnson; S D Shapiro; H G Welgus; R M Senior
Journal:  J Biol Chem       Date:  1996-02-23       Impact factor: 5.157

Review 5.  Matrix metalloproteinases: a review.

Authors:  H Birkedal-Hansen; W G Moore; M K Bodden; L J Windsor; B Birkedal-Hansen; A DeCarlo; J A Engler
Journal:  Crit Rev Oral Biol Med       Date:  1993

6.  Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis.

Authors:  B Zhang; S Ye; S M Herrmann; P Eriksson; M de Maat; A Evans; D Arveiler; G Luc; F Cambien; A Hamsten; H Watkins; A M Henney
Journal:  Circulation       Date:  1999-04-13       Impact factor: 29.690

7.  Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease.

Authors:  Stefan Blankenberg; Hans J Rupprecht; Odette Poirier; Christoph Bickel; Marek Smieja; Gerd Hafner; Jürgen Meyer; François Cambien; Laurence Tiret
Journal:  Circulation       Date:  2003-04-01       Impact factor: 29.690

8.  Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease.

Authors:  Angharad R Morgan; Baiping Zhang; William Tapper; Andrew Collins; Shu Ye
Journal:  J Mol Med (Berl)       Date:  2003-05-01       Impact factor: 4.599

9.  Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina.

Authors:  D L Brown; M S Hibbs; M Kearney; C Loushin; J M Isner
Journal:  Circulation       Date:  1995-04-15       Impact factor: 29.690

10.  Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat.

Authors:  M P Bendeck; N Zempo; A W Clowes; R E Galardy; M A Reidy
Journal:  Circ Res       Date:  1994-09       Impact factor: 17.367

View more
  12 in total

1.  Relationship between serum cytokines receptors and matrix metalloproteinase 9 levels and coronary artery disease.

Authors:  Seyed Reza Mirhafez; Amir Avan; Mohammad Tajfard; Shabnam Mohammadi; Mohsen Moohebati; Arash Fallah; Hamed Ghazavi; Hossein Savadi; Majid Ghayour Mobarhan
Journal:  J Clin Lab Anal       Date:  2016-12-02       Impact factor: 2.352

2.  Association of COL4A3 (rs55703767), MMP-9 (rs17576)and TIMP-1 (rs6609533) gene polymorphisms with susceptibility to type 2 diabetes.

Authors:  Samira Saravani; Davood Yari; Ramin Saravani; Changiz Azadi Ahmadabadi
Journal:  Biomed Rep       Date:  2017-02-09

3.  Association of Matrix Metalloproteinase-2 (MMP-2) and MMP-9 Promoter Polymorphisms, Their Serum Levels, and Activities with Coronary Artery Calcification (CAC) in an Iranian Population.

Authors:  Saeed Elahirad; Daniel Elieh Ali Komi; Amir Kiani; Ehsan Mohammadi-Noori; Asad Vaisi-Raygani; Hadi Mozafari; Fariborz Bahrehmand; Mohammadreza Saidi; Vahid Toupchi-Khosroshahi; Nahid Salehi
Journal:  Cardiovasc Toxicol       Date:  2021-11-03       Impact factor: 3.231

4.  Matrix metalloproteinase-9 gene polymorphisms and their interaction with environment on subarachnoid hemorrhage risk.

Authors:  Tao Wang; Wanxing Fu; Shuang Song; Yanlong Han; Lihong Yao; Youkui Lu; Junshuai Zheng; Jing Wang
Journal:  Exp Biol Med (Maywood)       Date:  2018-05

5.  Association between matrix metalloproteinases-2 and -9 gene polymorphism with basement membrane disruption in oral lichen planus: A case-control pilot study.

Authors:  Anubhuti Sood; Latha Mary Cherian; R Heera; Sanish Sathyan; Moinak Banerjee
Journal:  J Oral Biol Craniofac Res       Date:  2022-03-17

6.  Polymorphisms of the matrix metalloproteinase genes are associated with essential hypertension in a Caucasian population of Central Russia.

Authors:  Maria Moskalenko; Irina Ponomarenko; Evgeny Reshetnikov; Volodymyr Dvornyk; Mikhail Churnosov
Journal:  Sci Rep       Date:  2021-03-04       Impact factor: 4.379

7.  Matrix metalloproteinase 9 level as an indicator for restenosis following cervical and intracranial angioplasty and stenting.

Authors:  Jun-Peng Liu; Yin-Zhou Wang; Yong-Kun Li; Qiong Cheng; Zheng Zheng
Journal:  Neural Regen Res       Date:  2015-04       Impact factor: 5.135

8.  MMP9 polymorphism is associated with susceptibility to non-traumatic osteonecrosis of femoral head in a Chinese Han population.

Authors:  Yuan Liu; Yanfei Jia; Yuju Cao; Yan Zhao; Jieli Du; Feimeng An; Yuxin Qi; Xue Feng; Tianbo Jin; Jianping Shi; Jianzhong Wang
Journal:  Oncotarget       Date:  2017-08-24

9.  Association between matrix metalloproteinase 9 C-1562T polymorphism and the risk of coronary artery disease: an update systematic review and meta-analysis.

Authors:  Ming-Ming Zhang; Xue-Wei Chang; Xue-Qin Hao; Hao Wang; Xiang Xie; Shou-Yan Zhang
Journal:  Oncotarget       Date:  2017-12-15

10.  Plasma concentration, genetic variation, and gene expression levels of matrix metalloproteinase 9 in Iranian patients with coronary artery disease.

Authors:  Khalil Mahmoodi; Koorosh Kamali; Elham Karami; Mohammad Soleiman Soltanpour
Journal:  J Res Med Sci       Date:  2017-01-27       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.